Management of gout: beyond allopurinol.
The basic concepts of the pathogenesis and management of gout have not altered for many years. Monosodium urate monohydrate crystals drive the disease and identification of these crystals is required for certain diagnosis. In contrast, our understanding of the mediators of gouty inflammation, the appropriate target serum urate concentration during treatment, the drugs available and the best ways to use those drugs have all advanced in recent years and will be the focus of this review.
McGill
N W
NW
Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. neil.mcgill@sswahs.nsw.gov.au
D000493:Allopurinol / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D015415:Biomarkers / Q000097:blood; D019468:Disease Management; D006073:Gout / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D014527:Uric Acid / Q000037:antagonists & inhibitors / Q000097:blood*
D015415:Biomarkers; D014527:Uric Acid; D000493:Allopurinol